Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?

References

• GBD. 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11): 877–897.
   PubMed Web of Science ®Google Scholar
• Chan KY, Wang W, Wu JJ, et al. Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381(9882):2016–2023.
   PubMed Web of Science ®Google Scholar
• Fiest KM, Roberts JI, Maxwell CJ, et al. The prevalence and incidence of dementia due to Alzheimer’s disease: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(Suppl 1):S51–82.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Teijido O, Carril JC. Can cloud-based tools accelerate Alzheimer’s disease drug discovery? Expert Opin Drug Discov. 2016;11(3):215–223.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Torrellas C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323–556.
   PubMedGoogle Scholar
• Britt DMI, Day GS. Over-prescribed medications, under-appreciated risks: a review of the cognitive effects of anticholinergic medications in older adults. Mo Med. 2016;111(3):207–214.
   Google Scholar
• Pasqualetti G, Togniti S, Calsolaro V, et al. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–1466.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Mortsdorf T, et al. Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (NY). 2017;3(3):367–384.
   PubMedGoogle Scholar
• Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017;24(1):47.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Carrera I, et al. Novel therapeutic strategies for dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141–241.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang L, Lv M, et al. AlzPlatform: an Alzheimer’s disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model. 2015;54:1050–1060.
   Web of Science ®Google Scholar
• Kumar A, Nisha CM, Silakari C, et al. Current and novel therapeutic molecules and targets in Alzheimer’s disease. J Formosan Med Assoc. 2016;115:3–10.
   PubMed Web of Science ®Google Scholar
• McHardy SF, Wang HL, McCowen SV, et al. Recent advances in acetylcholinesterase inhibitors and reactivators: an update on the patent literature (2012–2015). Expert Opin Ther. 2017;27(4):455–476.
   Google Scholar
• Wattmo C, Londos E, Minthon L. Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease. BMC Neurology. 2014;14:173.
   PubMed Web of Science ®Google Scholar
• Meguro K, Kasai M, Akanuma K, et al. Donepezil and life expectancy in Alzheimer’s disease: a retrospective analysis in the Tajiri project. BMC Neurology. 2014;14:83.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Fernández-Novoa L, et al. Neuroimmune crosstalk in CNS disorders: the histamine connection. Curr Pharm Des. 2016;22(7):819–848.
   PubMed Web of Science ®Google Scholar
• Guzior N, Wieckowska A, Panek D, et al. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr Med Chem. 2015;22(3):373–404.
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Rosenberg RN. Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease. ImmunoTargets Ther. 2013;2:105–114.
   Google Scholar
• Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annals Neurol. 2014;76(2):185–205.
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Goñi F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron. 2015;85(6):1162–1176.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Osswald HL. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev. 2014;43(19):6765–6813.
   PubMed Web of Science ®Google Scholar
• Koelsch G. BACE1 function and inhibition: implications of intervention in the amyloid pathway of Alzheimer’s Disease pathology. Molecules. 2017;22:10. pii: E1723.
   Web of Science ®Google Scholar
• Tagami S, Yanagida K, Kodama TS, et al. Semagacestat is a pseudo-inhibitor of γ-secretase. Cell Rep. 2017;21(1):259–273.
   PubMed Web of Science ®Google Scholar
• Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer’s disease. Biochemistry. 2013;52(19):3197–3216.
   PubMed Web of Science ®Google Scholar
• Abushouk AI, Elmaraezy A, Aglan A, et al. Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials. BMC Neurol. 2017;17(1):66.
   PubMedGoogle Scholar
• Parsons CG, Rammes G. Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease. Expert Opin Investig Drugs. 2017;26(5):579–592.
   PubMed Web of Science ®Google Scholar
• Gold M. Phase II clinical trials of anti-amyloid β antibodies: when is enough, enough? Alzheimers Dement (N Y). 2017;3(3):402–409.
   PubMedGoogle Scholar
• Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12(2):110–120.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321.
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341–350.
   PubMed Web of Science ®Google Scholar
• Kohyama K, Matsumoto Y. Alzheimer’s disease and immunotherapy: what is wrong with clinical trials? ImmunoTargets Ther. 2015;4:27–34.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. BioMed Res Intern. 2016. ID 3245935. DOI:10.1155/2016/3245935
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM. Tau Immunotherapy. Neurodegener Dis. 2016;16(1–2):34–38.
   PubMed Web of Science ®Google Scholar
• Shahpasand K, Shamloo AS, Nabavi SM, et al. Tau immunotherapy: hopes and hindrances. Hum Vaccin Immunother. 2017. DOI:10.1080/21645515.2017.1393594
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–134.
   PubMed Web of Science ®Google Scholar
• Li C, Götz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov. 2017. DOI:10.1038/nrd.2017.155
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Painter MM, Bu G, et al. Apolipoprotein E as a therapeutic target in Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30(9):773–789.
   PubMed Web of Science ®Google Scholar
• Pankiewicz JE, Baquero-Buitrago J, Sanchez S, et al. APOE genotype differentially modulates effects of anti-Aβ, passive immunization in APP transgenic mice. Mol Neurodeg. 2017;12:12.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol. 2018. Epub ahead of print. DOI:10.2217/fnl-2017-0038
   Google Scholar
• Cacciatore I, Marinelli L, Fornasari E, et al. Novel NSAID-derived drugs for the potential treatment of Alzheimer’s disease. Int J Mol Sci. 2016;17(7):pii: E1035.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, Sancarlo D, Ruan Q, et al. Phytochemicals in the treatment of Alzheimer’s disease: a systematic review. Curr Drug Targets. 2017;18(13):1487–1498.
   PubMed Web of Science ®Google Scholar
• Libro R, Giacoppo S, Rajan TS, et al. Natural phytochemicals in the treatment and prevention of Dementia: an overview. Molecules. 2016;21:518.
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Wang J, Ho L, et al. Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochimica Biophysica Acta. 2015;1852:1202–1208.
   PubMed Web of Science ®Google Scholar
• Xu J, Lacoske MH, Theodorakis EA. Neurotrophic natural products: chemistry and biology. Angew Chem Int Ed Engl. 2014;53(4):956–987.
   PubMed Web of Science ®Google Scholar
• Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383–1391.
   PubMed Web of Science ®Google Scholar
• Shen JS, Zhou Q, Li P, et al. Update on phytochemistry and pharmacology of naturally occurring resveratrol oligomers. Molecules. 2017;22:2050.
   PubMed Web of Science ®Google Scholar
• Lei X, Yu J, Niu Q, et al. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides. Scientific Reports. 2015;5:16541.
   PubMed Web of Science ®Google Scholar
• Singh SK, Srivastav S, Yadav AK, et al. Overview of Alzheimer’s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal compounds. Oxid Med Cell Longevity. 2016; ID 7361613. DOI:10.1155/2016/7361613
   Web of Science ®Google Scholar
• Canevelli M, Adali N, Kelaiditi E, et al. Effects of gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine. 2014;21:888–892.
   PubMed Web of Science ®Google Scholar
• May BH, Feng M, Hyde AJ, et al. Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: a systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry. 2018;33(3):449-458
   Web of Science ®Google Scholar
• Teng E, Taylor K, Bilousova T, et al. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. Neurobiol Dis. 2015;82:552–560.
   PubMed Web of Science ®Google Scholar
• Asua D, Bougamra G, Calleja M, et al. Peptides acting as cognitive enhancers. Neuroscience. 2017;pii: S0306-4522(17)30721–2. DOI:10.1016/j.neuroscience.2017.10.002
   PubMed Web of Science ®Google Scholar
• Wu Y, Luo X, Liu X, et al. Intraperitoneal administration of a novel TAT-BDNF peptide ameliorates cognitive impairments via modulating multiple pathways in two Alzheimer’s rodent models. Scientific Reports. 2015;5:15032.
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy activates neuronal responses in Alzheimer’s disease. JAMA Neurol. 2015;72(10):1139–1147.
   PubMed Web of Science ®Google Scholar
• Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–1178.
   PubMed Web of Science ®Google Scholar
• Henderson VW. Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol. 2014;142:99–106.
   PubMed Web of Science ®Google Scholar
• Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. Plos Med. 2015;12(6):e1001833.
   PubMed Web of Science ®Google Scholar
• Stephenson D, Perry D, Carrillo MC, et al. Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Rev Neurother. 2015;15(3):327–333.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;1–11.doi: 10.1093/ijpnp/pyn115
   Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov. 2014;9(9):1059–1086.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014;75(6):348–365.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response. Int J Mol Sci. 2015;16:30483–30543.
   PubMed Web of Science ®Google Scholar
• Manczak M, Reddy PH. RNA silencing of genes involved in Alzheimer’s disease enhances mitochondrial function and synaptic activity. Biochimica Biophysica Acta. 2013;1832:2368–2378.
   PubMed Web of Science ®Google Scholar
• Choong CJ, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opin Biol Ther. 2016;16(2):143–159.
   PubMed Web of Science ®Google Scholar
• Haston KM, Finkbeiner S. Clinical trials in a dish: the potential of pluripotent stem cells to develop therapies for neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2016;56:489–510.
   PubMed Web of Science ®Google Scholar
• Arber C, Lovejoy C, Wray S. Stem cell models of Alzheimer’s disease: progress and challenges. Alzheimer Res Ther. 2017;9:42.
   PubMed Web of Science ®Google Scholar
• Lai S, Zhang M, Xu D, et al. Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment. Transl Neurodeg. 2015;4:7.
   PubMed Web of Science ®Google Scholar
• Navarro-Yepes J, Zavala-Flores L, Anandhan A, et al. Antioxidant gene therapy against neuronal cell death. Pharmacol Ther. 2014;142(2):206–230.
   PubMed Web of Science ®Google Scholar
• Törmälehto S, Martikainen J, Bell JS, et al. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer’s disease over a three-year period: kuopio ALSOVA study. Int Psychogeriatr. 2017;29(10):1723–1733.
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Lolk A, Rodrigo-Domingo M, et al. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur Psychiatry. 2017;42:14–23.
   PubMed Web of Science ®Google Scholar
• Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1):pii: e002080.
   Web of Science ®Google Scholar
• Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: medicare cohort study. J Am Geriatr Soc. 2016;64(8):1540–1548. [ Epub 2016 Jun 24].
   PubMed Web of Science ®Google Scholar
• Tsolaki M, Papaliagkas V, Frisoni G, et al. MCI patients in europe: medication and comorbidities. The DESCRIPA study. Curr Alzheimer Res. 2016;13(12):1407–1413.
   PubMed Web of Science ®Google Scholar
• Kadohara K, Sato I, Doi Y, et al. Prescription patterns of medications for Alzheimer’s disease in Japan from 2010 to 2015: a descriptive pharmacy claims database study. Neurol Ther. 2017;6(1):25–37.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C, Teijido O, et al. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics. 2016;17(9):1041–1074.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics. 2016;1(2):151–209.
   Google Scholar
• Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251–283.
   PubMed Web of Science ®Google Scholar
• Brodney MA, Beck EM, Butler CR, et al. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem. 2015;58(7):3223–3252.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Meyyazhagan A, Carril JC, et al. Pharmacogenetics of vascular risk factors in Alzheimer’s disease. J Pers Med. 2018;8:3.
   PubMed Web of Science ®Google Scholar